What are the current guideline recommendations for managing hypertension in patients with chronic kidney disease?

Management of Hypertension in CKD: Current Guidelines

For patients with chronic kidney disease and hypertension, target a systolic blood pressure <120 mmHg using standardized office measurement, and initiate therapy with ACE inhibitors or ARBs in those with proteinuria (urinary protein >500 mg/24h or albumin-to-creatinine ratio >30 mg/mmol), adding thiazide or loop diuretics and other agents as needed to reach target. 1, 2

Blood Pressure Targets

The most recent and authoritative guidance comes from the 2021 KDIGO guidelines, which represent a significant shift from previous recommendations:

• Target SBP <120 mmHg when tolerated, using standardized office BP measurement (not routine office measurement) 1, 2
• This is a conditional recommendation (Grade 2B), acknowledging that individualization is appropriate for patients with very limited life expectancy or symptomatic postural hypotension 1

Critical caveat: This <120 mmHg target applies only to standardized office BP measurements—applying this target to routine office measurements risks dangerous overtreatment 1, 2. Standardized measurement requires:

• Patient seated quietly for 5 minutes before measurement
• Proper positioning and cuff size
• Multiple measurements averaged
• Absence of talking during measurement

The older Canadian guidelines 3, 4 recommended <130/80 mmHg for nondiabetic CKD, which is now superseded by the more intensive KDIGO target based on cardiovascular mortality benefits demonstrated in the SPRINT trial 2.

First-Line Pharmacotherapy Algorithm

For Proteinuric CKD (urinary protein >500 mg/24h or ACR >30 mg/mmol):

Step 1: Start with ACE inhibitor (Grade A) or ARB if ACE inhibitor not tolerated (Grade B) 3, 4, 1

• Use the highest approved dose tolerated to achieve proven benefits 1
• Monitor serum creatinine and potassium within 2-4 weeks of initiation 1
• Continue therapy unless creatinine rises >30% within 4 weeks 1

Step 2: Add thiazide/thiazide-like diuretic for additive effect (Grade D) 3, 4

• Switch to loop diuretic if volume overload present or eGFR significantly reduced (Grade D) 3, 4

Step 3: Add calcium channel blocker (typically dihydropyridine) if target not reached 5, 1

Step 4: Most patients require combination therapy with multiple agents to reach target BP 3, 4

For Non-Proteinuric CKD:

• Target BP <140/90 mmHg (Grade B) per 2017 Canadian guidelines 6, though KDIGO 2021 suggests <120 mmHg may be reasonable 1
• Do NOT combine ACE inhibitor + ARB in non-proteinuric CKD (Grade B) 3, 4, 6
• RAS inhibitors may be reasonable but are not mandatory without albuminuria 1

Critical Contraindications and Monitoring

Avoid ACE inhibitor + ARB + direct renin inhibitor combinations in all CKD patients (Grade 1B) 1—this triple combination increases adverse events without benefit.

For bilateral renovascular disease or solitary kidney with renal artery stenosis: Exercise extreme caution with ACE inhibitors/ARBs due to acute renal failure risk (Grade D) 3, 4

Hyperkalemia management: Rather than stopping RAS inhibitors when hyperkalemia develops, implement potassium-lowering measures first (dietary restriction, potassium binders) to maintain the cardiovascular and renal benefits of these agents 1

Acceptable creatinine rise: Continue ACE inhibitor/ARB unless creatinine increases >30% within 4 weeks of initiation 1. Smaller increases are expected and acceptable.

Emerging Therapies

While not traditional antihypertensives, SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists provide cardiovascular and renal protection in CKD patients 5, 7. However, Hypertension Canada acknowledges these are not approved specifically for hypertension treatment 5.

Mineralocorticoid receptor antagonists (spironolactone, eplerenone) are effective for refractory hypertension but require careful monitoring for hyperkalemia, particularly with low eGFR 1.

Key Differences from Older Guidelines

The 2009-2011 Canadian guidelines 3, 4 recommended <130/80 mmHg targets, which have been superseded by the more intensive <120 mmHg systolic target from KDIGO 2021 1, 2. This change reflects evidence that more intensive BP control reduces cardiovascular and all-cause mortality, even though effects on CKD progression remain uncertain 2.

The emphasis on standardized BP measurement is new and critical—routine office measurements average 5-10 mmHg higher than standardized measurements, making the distinction between measurement techniques essential for safe implementation of lower targets 2.